Pharmacovigilance and teratogen 2008;Pharmacovigilance et tératovigilance 2008

Revue Medicale Suisse

Volumn 5, Issue 186, 2009, Pages 130-134

  Livio, Françoise ^a   Ivanyuk, Anton ^a   Biollaz, Jérôme ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; BOTULINUM TOXIN A; CEFEPIME; DARUNAVIR; EFALIZUMAB; EZETIMIBE PLUS SIMVASTATIN; HALOPERIDOL; HLA B57 ANTIGEN; LAPATINIB; LENALIDOMIDE; MOXIFLOXACIN; MYCOPHENOLIC ACID; NATALIZUMAB; NEUROLEPTIC AGENT; PEGINTERFERON ALPHA2A; PERGOLIDE MESILATE; POSACONAZOLE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RIMONABANT; RITUXIMAB; ROTIGOTINE; TELBIVUDINE; TERATOGENIC AGENT; VARENICLINE;

DEMENTIA; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GERIATRIC CARE; HUMAN; HYPERSENSITIVITY; MENTAL DISEASE; MORTALITY; NEOPLASM; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SCREENING; TIME; ARTICLE; CONGENITAL MALFORMATION; DRUG THERAPY; POSTMARKETING SURVEILLANCE;

ABNORMALITIES, DRUG-INDUCED; DRUG THERAPY; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 58949092528     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 2007;370: 1706-13.
2. FDA briefing document: Rimonabant tablets 20 mg Rockville FDA 2007. www.fda.gov/OHRMS/DOCKETS/AC/07/briefing
3. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. www.cochrane.org/reviews/en/ab006103.html
4. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax 2008;63:717-24.
5. Pinget C, Martin E, Wasserfallen JB, Humair JP. Cornuz J. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling. Eur J Cardiovasc Prev Rehab 2007;14:451-5.
6. ** Klein-Schwartz W.Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002;14:219-23.
7. Maher B. Poll results: Look who's doping. Nature 2008;452:674-5.
8. Novak SP, Kroutil LA, Williams RL, et al. The non-medical use of prescription ADHD medications. Results from a national Internet panel. Subst Abuse Treat Prev Policy 2007;2:32.
9. Bright G. Abuse of medications employed for the treatment results from a large-scale community survey. Medscape J Med 2008;10;111.
10. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
11. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional versus atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
12. Jeste DV, Blazer D, Casey D, et al. Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008;33:957-70.
13. ** Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008;300;1887-96.
14. * Greenland P. Lloyd-Jones D. Critical lessons from the ENHANCE trial. JAMA 2008;299:953-5.
15. * Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56.
16. Bradford PG, Awad AB. Phytosterols as anticancer compounds. Mol Nutr Food Res 2007;51:161-70.
17. Peto R, Embersome J, Landray M, et al. Analysis of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-66.
18. www.fda.gov/cder/drug/infopage/RHE/aranesp/packageinsert.pdf
19. Mallal MB, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
20. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients. J Acquir Immune Defic Syndr 2007;46:24-31.
21. www.fda.gov/cder/drug/InfoSheets/HCP/mycophelolateHCP.htm
22. * Vento M, Perez Aytes A, Ledo A, et al. Mycophenolate mofetil during pregnancy: Some words of caution. Pediatrics 2008;122:184-5.
23. http://afssaps.sante.fr/htm/10/filltrpsc/lp071201.pdf